Skip to main
QURE

uniQure (QURE) Stock Forecast & Price Target

uniQure (QURE) Analyst Ratings

Based on 11 analyst ratings
Buy
Strong Buy 36%
Buy 36%
Hold 27%
Sell 0%
Strong Sell 0%

Bulls say

uniQure is poised for success with their robust pipeline, particularly with the potential for accelerated approval of AMT-130 and their partnership with Bristol Myers Squibb. However, clinical and regulatory risks must be taken into account and their heavy reliance on the success of AMT-130 poses a potential risk to their business. Additionally, competition in the market and challenges with marketing and commercialization may impact their success. A price target of $37 is based on probability-adjusted modeling of key franchises, with a DCF valuation and WACC of 11.2%.

Bears say

uniQure is a relatively young company with limited revenue streams and high research and development costs, resulting in negative earnings. The success of their pipeline products is uncertain, and any setbacks could have a significant impact on their financials. Additionally, their partnership with Bristol Myers Squibb for cardiovascular diseases may not provide meaningful revenue in the near term. These factors add to the overall risk profile of the company, leading to a negative outlook on their stock.

uniQure (QURE) has been analyzed by 11 analysts, with a consensus rating of Buy. 36% of analysts recommend a Strong Buy, 36% recommend Buy, 27% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of uniQure and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About uniQure (QURE) Forecast

Analysts have given uniQure (QURE) a Buy based on their latest research and market trends.

According to 11 analysts, uniQure (QURE) has a Buy consensus rating as of May 5, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $43.27, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $43.27, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

uniQure (QURE)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.